Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity

Cunha, Burke A.; Eisenstein, Lawrence; Hamid, Naveed S.

doi:10.1016/j.hrtlng.2005.09.010

Cited by 58 publications

(40 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical experience with 1 patient and a study involving 12 healthy volunteers indicate that doses of 12 mg/kg can be administered over 6 14 days without any toxicity [45,54] . Although currently this dosing regimen cannot be recommended, these experiences illustrate that higher doses are indicated in select cases and that such doses might be approved in the future (e.g.…”

Section: Dosing Regimensmentioning

confidence: 99%

Daptomycin: A Review 4 Years after First Approval

Sauermann

Rothenburger

Graninger³

et al. 2007

Pharmacology

134

124

View full text Add to dashboard Cite

Daptomycin is the first approved member of a new class of antibiotics, namely the cyclic lipopeptides. Daptomycin has rapid bactericidal activity against Gram-positive pathogens. It acts by penetrating into the bacterial cell wall with consecutive formation of pores, loss of electrical membrane potential and inhibition of peptidoglycan synthesis. As the mode of action of daptomycin is ‘concentration-dependent’, the pharmacokinetic/pharmacodynamic indices that correlate best with its activity are the ratios of the peak concentration (C_max) to minimum inhibitory concentration (MIC) or the area under the curve (24-hour AUC) to MIC. Daptomycin should be administered intravenously once daily, because adverse effects on skeletal muscle associated with an increase in plasma levels of creatine phosphokinase and myopathy were observed more frequently at shorter dosing intervals. Overall, the rate of adverse events during daptomycin therapy is comparable to that of other standard regimens. Daptomycin was shown to be not inferior to antimicrobial standard therapy and therefore was approved for complicated skin and skin structure infections at a dose of 4 mg/kg, for Staphylococcus aureus bacteremia and right-sided endocarditis at a dose of 6 mg/kg. Dosage regimens remain a matter of discussion, and an increase in the currently approved doses from 4–6 to 6–8 mg/kg per day for severe infections seems promising. Though not approved up to now, daptomycin appears to be a treatment alternative for Gram-positive bone and joint infections based on clinical observations. Large international studies showed high susceptibility of relevant Gram-positive pathogens to daptomycin, even in multidrug-resistant strains. Thus, treatment of infections caused by Gram-positive cocci resistant to other antimicrobial drugs is a potential indication of daptomycin. Since glycopeptides and daptomycin have the same target site, there appears to be a risk of reduced susceptibility to both drugs after consecutive use. Therefore, daptomycin should be used with caution for treatment of vancomycin-resistant isolates or after prior vancomycin (glycopeptide) therapy. This review describes the history, mechanism of action, susceptibility, recent discoveries and clinical experience regarding daptomycin, discussing its current role in the field of infectious diseases.

show abstract

Section: Dosing Regimensmentioning

confidence: 99%

Daptomycin: A Review 4 Years after First Approval

Sauermann

Rothenburger

Graninger³

et al. 2007

Pharmacology

134

124

View full text Add to dashboard Cite

show abstract

“…However, a recent case report demonstrated that daptomycin treatment of catheter-related MSSA acute endocarditis led to a cure after the failure of 3 weeks of high-dose cefazolin treatment to eradicate a tricuspid valve vegetation (10). Another case report showed that high-dose, prolonged therapy with daptomycin resolved both pacemaker-induced S. aureus acute bacterial endocarditis and persistent S. aureus bacteremia resulting from an infected coronary stent (9). A third case report also demonstrated the efficacy of daptomycin concurrently administered systemically and via ALT for 14 days in a patient with S. epidermidis bacteremia who had failed vancomycin therapy (18).…”

Section: Discussionmentioning

confidence: 99%

Daptomycin Antibiotic Lock Therapy in a Rat Model of Staphylococcal Central Venous Catheter Biofilm Infections

Praagh

Zhang

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…Según estos resultados y los ensayos clíni-cos publicados [19][20][21] , la daptomicina constituiría, en sus indicaciones clínicas, una excelente opción terapéutica para las infecciones graves por microorganismos grampositivos, incluyendo los multirresistentes. …”

Section: Discussionunclassified

“…La tasa de mutantes resistentes espontáneas in vitro a la daptomicina es baja 14 , pero se han encontrado algunos aislados clí-nicos de S. aureus y Enterococcus con sensibilidad disminuida a este compuesto [15][16][17][18] . Los ensayos clínicos realizados hasta la fecha con daptomicina demuestran su equivalencia frente a tratamientos estándares en infecciones de piel y de tejidos blandos, bacteriemia y endocarditis bacteriana [19][20][21] . Actualmente, los microorganismos grampositivos ocupan una posición destacada entre los patógenos de importancia clínica debido a su frecuencia, la virulencia natural de especies como S. aureus, Streptococcus pneumoniae y estreptococos betahemolíticos y su tendencia a desarrollar un perfil de multirresistencia a los antimicrobianos 22 .…”

Section: Introductionunclassified